John Hood is at it again.
In 2016, Hood started a company, Impact BioMedicines, around a medicine that had been abandoned by the drug giant Sanofi. Impact raised $22 million in October 2017, and then was purchased in January 2018 by Celgene for more than $2 billion.
About the Author Reprints
